Diadexus, Inc. Share Price

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2T 43.14T 39.76T 37.23T 69.81T 46.41L 71.26T 5L 2L 22.94L 2L 2L 79.54L	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	52.9L 46.38L 42.76L 40.03L 75.06L 50Cr 76.62L 5.14Cr 1.99Cr 25Cr 1.99Cr 1.94Cr 86Cr	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/21/17	Diadexus, Inc. Went Out of Business	CI
08/18/08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/18/09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/16/01	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/16/29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/16/29	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/16/20	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/16/07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/16/07	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/16/13	Diadexus, Inc. Filed for Bankruptcy	CI
10/16/10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/16/23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/16/30	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	+5.20%	+12.14%	-15.74%	-36.62%	302.13Cr
SAREPTA THERAPEUTICS, INC.	+5.18%	-3.88%	-1.52%	-84.16%	177.9Cr
BIONOTE, INC.	-1.69%	-5.93%	-13.74%	-7.03%	29Cr
Average	+2.17%	+0.84%	-10.33%	-42.60%	127.21Cr
Weighted average by Cap.	+4.80%	+5.57%	-10.66%	-51.57%

	2014	2015
Net sales	2.61Cr 2.29Cr 2.11Cr 1.98Cr 3.7Cr 246.32Cr 3.78Cr 25Cr 9.81Cr 121.74Cr 9.81Cr 9.59Cr 422.13Cr	1.79Cr 1.57Cr 1.45Cr 1.35Cr 2.54Cr 168.7Cr 2.59Cr 17Cr 6.72Cr 83Cr 6.72Cr 6.57Cr 289.12Cr
Net income	-84.67L -74.24L -68.43L -64.07L -1.2Cr -80Cr -1.23Cr -8.22Cr -3.18Cr -39Cr -3.18Cr -3.11Cr -136.88Cr	-71.66L -62.83L -57.92L -54.22L -1.02Cr -68Cr -1.04Cr -6.96Cr -2.69Cr -33Cr -2.69Cr -2.63Cr -115.85Cr
Net Debt	-2L -2L -2L -1L -3L -1.87Cr -3L -19.23L -7L -92.31L -7L -7L -3.2Cr	52.41L 45.95L 42.36L 39.66L 74.36L 49Cr 75.91L 5.09Cr 1.97Cr 24Cr 1.97Cr 1.93Cr 85Cr

Diadexus, Inc. Share Price

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile